EDIT vs UTHR · rev $32.3M vs P/E 20, rev $2.88B
Editas Medicine Inc (EDIT) versus United Therapeutics Corporation (UTHR) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
United Therapeutics Corporation (UTHR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported UTHR revenue for 2024-12-31 was $2.88B. Net income was $1.20B. Revenue was up 23.6% from 2023-12-31 to 2024-12-31. UTHR currently screens at market cap $23.41B and trailing P/E 20.4.
EDIT currently screens at market cap $375.2M. UTHR currently screens at market cap $23.41B and trailing P/E 20.4.
Not investment advice. Open the EDIT and UTHR stock pages for the full models.
Not investment advice.